Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00311870

Enrollment

Registered

2006-04-06

Start date

1993-03-31

Completion date

1999-04-30

Last updated

2006-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Nephropathy

Brief summary

The aim of the study was to compare the renoprotective effect of a long acting calcium antagonist (nisoldipine) with an angiotensin converting enzyme inhibitor (lisinopril)in type 1 diabetic patients with diabetic kidney disease. In total, 51 patients were randomised to treatment with one of these drugs for 4 years. Changes in kidney function, blood pressure and urinary excretion of albumin were measured every 6 months

Interventions

DRUGnisoldipine

DRUGlisinopril

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Inclusion criteria

* diabetic nephropathy, type 1 diabetes, hypertension

Exclusion criteria

* child bearing potential, non-diabetic kidney disease, malignancy

Design outcomes

Primary

Measure	Time frame
change in glomerular filtration rate from study start to study end	—

Secondary

Measure	Time frame
blood pressure response	—
change in urinary albumin excretion rate	—

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026